MyX Therapeutics Presents at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) Conference
MONTREAL--(BUSINESS WIRE)-- #MyXdelivery--MyX Therapeutics Inc, a unique enabling mucosal delivery platform company, announces new data from preclinical studies confirming MyX’s mucosal targeting nanoparticle eye drop formulation allows once-a-week dosing. Dr Frank Gu, co-founder and Chief Scientific Officer (CSO), will present these data, today October 7, 2019 at the 9th annual Partnership Opportunities in Drug Delivery (PODD) conference, at 5:45 p.m. Eastern Time. "MyX-001 data suggests a significant R&